BRIDGE - Blocking Receptor of IL-1β for Donor Graft Edema Reduction

This study will determine if primary graft dysfunction (which causes low blood oxygen levels and fluid or inflammation in the lungs) after lung transplant can be prevented through the use of the study drug (IL-1 receptor antagonist, Anakinra). In this study, lung transplant participants who are randomized to the treatment group will have the study drug injected into the solution that their donor lungs are kept in prior to transplant.

NCT Number	NCT07410312
Lead Sponsor	Northwestern University
Conditions	Lung Transplant Recipient
Enrollment	20 participants
Start Date	2026-07-01
Primary Completion	2027-08 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2026-06-25